HRP20220884T1 - Proteini specifični za baff i b7rp1 i njihova uporaba - Google Patents
Proteini specifični za baff i b7rp1 i njihova uporaba Download PDFInfo
- Publication number
- HRP20220884T1 HRP20220884T1 HRP20220884TT HRP20220884T HRP20220884T1 HR P20220884 T1 HRP20220884 T1 HR P20220884T1 HR P20220884T T HRP20220884T T HR P20220884TT HR P20220884 T HRP20220884 T HR P20220884T HR P20220884 T1 HRP20220884 T1 HR P20220884T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino acid
- host cell
- acid sequence
- seq
- cell according
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title claims 13
- 108090000623 proteins and genes Proteins 0.000 title claims 13
- 210000004027 cell Anatomy 0.000 claims 34
- 125000003275 alpha amino acid group Chemical group 0.000 claims 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 3
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 3
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 3
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 230000001580 bacterial effect Effects 0.000 claims 3
- 230000009466 transformation Effects 0.000 claims 3
- 210000005253 yeast cell Anatomy 0.000 claims 3
- 241000238631 Hexapoda Species 0.000 claims 2
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims 2
- 102100034980 ICOS ligand Human genes 0.000 claims 2
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 claims 2
- 101710181056 Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 238000000844 transformation Methods 0.000 claims 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 1
- 241000282693 Cercopithecidae Species 0.000 claims 1
- 241000699800 Cricetinae Species 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims 1
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 claims 1
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 claims 1
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 claims 1
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims 1
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 claims 1
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims 1
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 229910001628 calcium chloride Inorganic materials 0.000 claims 1
- 239000001110 calcium chloride Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000004520 electroporation Methods 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Claims (17)
1. Stanica domaćina koja sadrži nukleinsku kiselinu koja kodira bispecifični protein, i/ili vektor koji sadrži nukleinsku kiselinu koja kodira bispecifični protein, naznačena time što bispecifični protein sadrži:
(a) polipeptid koji sadrži aminokiselinsku sekvencu koja ima sljedeću formulu:
A-L1-P-L2-P, pri čemu je A imunoglobulinski teški lanac IgG protutijela, L1 je prva peptidna poveznica koja je odsutna ili je dugačka 3 do 40 aminokiselina, P je BAFF-vezujući peptid koji je dug 10 do 40 aminokiselina, i L2 je druga peptidna poveznica koja je odsutna ili je dugačka 5 do 50 aminokiselina, i
(b) laki lanac imunoglobulina IgG protutijela,
pri čemu imunoglobulinski teški lanac (a) i imunoglobulinski laki lanac (b) tvore IgG protutijelo, koje se sastoji od dvije molekule polipeptida (a) i dvije molekule lakog lanca (b), koje može vezati B7RP1, i
pri čemu protein može inhibirati BAFF-om posredovanu proliferaciju ljudskih B stanica, i
pri čemu protein može inhibirati B7RP1- posredovanu proliferaciju ljudskih T stanica, i
pri čemu je stanica domaćin bakterijska stanica, stanica kvasca, stanica insekta, biljna stanica ili stanica sisavca.
2. Stanica domaćin prema zahtjevu 1, naznačena time što bispecifični protein sadrži teški lanac imunoglobulina kojemu nedostaje lizin na C-terminalnom kraju odmah uzvodno od L1.
3. Stanica domaćin prema zahtjevu 1, naznačena time što je IgG protutijelo je ljudsko ili humanizirano anti-B7RP1 IgG1 protutijelo.
4. Stanica domaćin prema zahtjevu 1 ili 2, naznačena time što je anti-B7RP1 protutijelo ljudsko ili humanizirano IgG2 protutijelo, ili ljudsko ili humanizirano IgG4 protutijelo.
5. Stanica domaćin prema bilo kojem od zahtjeva 1-4, naznačena time što P ima sekvencu aminokiselina SEQ ID NO:1 (LPGCKWDLLIKQWVCDPL).
6. Stanica domaćin prema bilo kojem od zahtjeva 1-5, naznačena time što L1 ima aminokiselinsku sekvencu SEQ ID NO:40 (GGGGG).
7. Stanica domaćin prema bilo kojem od zahtjeva 1-6, naznačena time što L2 ima aminokiselinsku sekvencu SEQ ID NO:5, poželjno pri čemu L2 ima aminokiselinsku sekvencu SEQ ID NO:6 ili SEQ ID NO:7.
8. Stanica domaćin prema bilo kojem od zahtjeva 1-7, naznačena time što kodira CDR1 lakog lanca koji sadrži aminokiselinsku sekvencu SEQ ID NO:8 (RASQGISNWLA), CDR2 lakog lanca koji sadrži aminokiselinsku sekvencu SEQ ID NO:9 (AASSLQS), CDR3 lakog lanca koji sadrži aminokiselinsku sekvencu SEQ ID NO:10 (QQYDSYPRT) , CDR1 teškog lanca koji sadrži aminokiselinsku sekvencu SEQ ID NO:11 (SYWMS), CDR2 teškog lanca koji sadrži aminokiselinsku sekvencu SEQ ID NO:12 (YIKQDGNEKYYVDSVKG), i CDR3 teškog lanca koji sadrži aminokiselinsku sekvencu SEQ ID NO:13 (EGILWFGDLPTF).
9. Stanica domaćin prema bilo kojem od zahtjeva 1-8, naznačena time što kodirani bispecifični protein sadrži varijabilnu regiju lakog lanca imunoglobulina koja sadrži aminokiselinsku sekvencu SEQ ID NO:14.
10. Stanica domaćin prema bilo kojem od zahtjeva 1-9, naznačena time što kodirani bispecifični protein sadrži varijabilnu regiju teškog lanca imunoglobulina koja sadrži aminokiselinsku sekvencu SEQ ID NO:15.
11. Stanica domaćin prema bilo kojem od zahtjeva 5-10, naznačena time što laki lanac imunoglobulina iz (b) sadrži aminokiselinsku sekvencu SEQ ID NO:19.
12. Stanica domaćin prema bilo kojem od zahtjeva 5-11, naznačena time što polipeptid iz (a) sadrži aminokiselinsku sekvencu SEQ ID NO:17 ili 18.
13. Stanica domaćin prema zahtjevu 1, naznačena time što polipeptid (a) sadrži aminokiselinsku sekvencu SEQ ID NO:17 ili SEQ ID NO:18, a polipeptid (b) sadrži aminokiselinsku sekvencu SEQ ID NO:19.
14. Stanica domaćin prema zahtjevu 1, naznačena time što bispecifični protein sadrži aminokiselinske sekvence SEQ ID NO:1, SEQ ID NO:14 i SEQ ID NO:15, poželjno, pri čemu protein nadalje sadrži poveznicu koja sadrži aminokiselinsku sekvencu SEQ ID NO:6 ili SEQ ID NO:7.
15. Stanica domaćin prema bilo kojem od zahtjeva 1-14, naznačena time što je stanica domaćin stanica sisavca odabrana iz skupine koju čine stanica jajnika kineskog hrčka (CHO), stanica bubrega bebe hrčka (BHK), stanica bubrega majmuna, stanica HeLa, stanica ljudskog hepatocelularnog karcinoma i stanica 293.
16. Postupak za izradu bispecifičnog proteina koji uključuje uzgoj stanice domaćina prema bilo kojem od zahtjeva 1-14 pod takvim uvjetima da se eksprimira nukleinska kiselina i obnavljanje proteina iz stanične mase ili medija kulture, pri čemu je stanica domaćin bakterijska stanica, stanica kvasca, stanica insekta ili biljna stanica.
17. Postupak prema zahtjevu 16, naznačena time što se nukleinska kiselina ili vektor uvodi u stanicu pomoću
(a) elektroporacije ili transformacije kalcijevim kloridom, pri čemu je stanica domaćin bakterijska stanica, ili
(b) transformacije litijevim acetatom ili transformacije polietilen glikolom, pri čemu je stanica domaćin stanica kvasca.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361780260P | 2013-03-13 | 2013-03-13 | |
US201461942776P | 2014-02-21 | 2014-02-21 | |
EP18182864.1A EP3456344B1 (en) | 2013-03-13 | 2014-03-12 | Proteins specific for baff and b7rp1 and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20220884T1 true HRP20220884T1 (hr) | 2022-10-14 |
Family
ID=50483540
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20220884TT HRP20220884T1 (hr) | 2013-03-13 | 2014-03-12 | Proteini specifični za baff i b7rp1 i njihova uporaba |
HRP20181629TT HRP20181629T1 (hr) | 2013-03-13 | 2018-10-10 | Proteini specifični za baff i b7rp1 i njihove upotrebe |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20181629TT HRP20181629T1 (hr) | 2013-03-13 | 2018-10-10 | Proteini specifični za baff i b7rp1 i njihove upotrebe |
Country Status (36)
Country | Link |
---|---|
US (3) | US10421823B2 (hr) |
EP (3) | EP3456344B1 (hr) |
JP (2) | JP6523243B2 (hr) |
KR (2) | KR102218723B1 (hr) |
CN (2) | CN110437336A (hr) |
AP (1) | AP2015008768A0 (hr) |
AU (1) | AU2014244498B2 (hr) |
CA (1) | CA2904992C (hr) |
CL (1) | CL2015002600A1 (hr) |
CR (1) | CR20150544A (hr) |
CY (1) | CY1120569T1 (hr) |
DK (2) | DK2968491T3 (hr) |
EA (1) | EA035388B1 (hr) |
ES (2) | ES2923909T3 (hr) |
HK (1) | HK1218885A1 (hr) |
HR (2) | HRP20220884T1 (hr) |
HU (2) | HUE040169T2 (hr) |
IL (1) | IL241281B (hr) |
JO (2) | JOP20140087B1 (hr) |
LT (2) | LT3456344T (hr) |
MX (2) | MX369502B (hr) |
MY (2) | MY171938A (hr) |
NZ (2) | NZ711954A (hr) |
PE (1) | PE20151772A1 (hr) |
PH (1) | PH12015502074A1 (hr) |
PL (2) | PL2968491T3 (hr) |
PT (2) | PT2968491T (hr) |
RS (2) | RS57689B1 (hr) |
SG (1) | SG11201507208VA (hr) |
SI (2) | SI2968491T1 (hr) |
TN (1) | TN2015000414A1 (hr) |
TW (1) | TWI603978B (hr) |
UA (1) | UA120034C2 (hr) |
UY (1) | UY35396A (hr) |
WO (1) | WO2014159725A1 (hr) |
ZA (1) | ZA201506708B (hr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1970077A (zh) * | 2001-05-11 | 2007-05-30 | 安姆根有限公司 | 与tall-1结合的肽和相关分子 |
US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
JOP20140087B1 (ar) | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
ITUB20151014A1 (it) * | 2015-05-27 | 2016-11-27 | Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro | Ligandi del recettore b7h nel trattamento di osteopenia e osteoporosi |
CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
AU2019313945A1 (en) * | 2018-07-31 | 2021-03-18 | Osaka University | Highly versatile method for granting new binding specificity to antibody |
Family Cites Families (138)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
US4970154A (en) | 1987-10-09 | 1990-11-13 | Baylor College Of Medicine | Method for inserting foreign genes into cells using pulsed radiofrequency |
US5106627A (en) | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
US6018026A (en) | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
WO1990014363A1 (en) | 1989-05-19 | 1990-11-29 | Amgen Inc. | Metalloproteinase inhibitor |
US5676954A (en) | 1989-11-03 | 1997-10-14 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
US6641809B1 (en) | 1990-03-26 | 2003-11-04 | Bristol-Myers Squibb Company | Method of regulating cellular processes mediated by B7 and CD28 |
US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
EP0546073B1 (en) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
JPH06508035A (ja) | 1991-06-14 | 1994-09-14 | ディーエヌエックス コーポレーション | トランスジェニックブタにおけるヒトヘモグロビンの生産 |
US5733731A (en) | 1991-10-16 | 1998-03-31 | Affymax Technologies N.V. | Peptide library and screening method |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1993015722A1 (en) | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Controlled delivery of pharmaceuticals from preformed porous microparticles |
US5417972A (en) | 1993-08-02 | 1995-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM |
DK0802800T3 (da) | 1993-08-12 | 2002-10-07 | Neurotech Sa | Biokompatible immunoisolatoriske kapsler indeholdende genetisk ændrede celler for levering af biologisk aktive molekyler |
US6268212B1 (en) | 1993-10-18 | 2001-07-31 | Amgen Inc. | Tissue specific transgene expression |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
US5484720A (en) | 1994-09-08 | 1996-01-16 | Genentech, Inc. | Methods for calcium phosphate transfection |
DE4435919C1 (de) | 1994-10-07 | 1995-12-07 | Deutsches Krebsforsch | Zinkfinger-DNA, -Protein und ihre Verwendung |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
AU705035B2 (en) | 1995-06-07 | 1999-05-13 | Baylor College Of Medicine | Nucleic acid transporters for delivery of nucleic acids into a cell |
US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
US5679559A (en) | 1996-07-03 | 1997-10-21 | University Of Utah Research Foundation | Cationic polymer and lipoprotein-containing system for gene delivery |
CA2267139A1 (en) | 1996-10-08 | 1998-04-16 | Ton Logtenberg | Methods and means for selecting peptides and proteins having specific affinity for a target |
BR9612752A (pt) | 1996-10-25 | 2000-01-18 | Human Genome Sciences Inc | Neutrocina |
US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
ES2301183T3 (es) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
AU5705898A (en) | 1996-12-17 | 1998-07-15 | Schering Corporation | Mammalian cell surface antigens; related reagents |
US7112655B1 (en) | 1997-02-27 | 2006-09-26 | Japan Tobacco, Inc. | JTT-1 protein and methods of inhibiting lymphocyte activation |
JP3521382B2 (ja) | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
US5969102A (en) | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
CA2232743A1 (en) | 1997-04-02 | 1998-10-02 | Smithkline Beecham Corporation | A tnf homologue, tl5 |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
CA2292835A1 (en) | 1997-06-06 | 1998-12-10 | Regeneron Pharmaceuticals, Inc. | Ntn-2 member of tnf ligand family |
IL133315A0 (en) | 1997-06-06 | 2001-04-30 | Regeneron Pharma | Ntn-2 member of tnf ligand family |
WO1999011791A2 (en) | 1997-09-05 | 1999-03-11 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
EE200000148A (et) | 1997-09-12 | 2001-02-15 | Biogen, Incorporated | Kay - uus immuunsüsteemi valk |
DE19821060A1 (de) | 1997-09-23 | 1999-04-15 | Bundesrepublik Deutschland Let | Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung |
ES2279585T3 (es) | 1997-09-23 | 2007-08-16 | Bundesrepublik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Instituts | Polipeptido coestimulante de celulas t, anticuerpos monoclonales, su preparacion y su uso. |
AU2212299A (en) | 1998-01-05 | 1999-07-26 | Genentech Inc. | Compositions and methods for the treatment of tumor |
WO1999062951A1 (en) | 1998-06-04 | 1999-12-09 | Shanghai Second Medical University | A human zinc finger protein gene (bmzf3) |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
KR100699524B1 (ko) | 1999-01-07 | 2007-03-23 | 지모제넥틱스, 인코포레이티드 | 가용성 수용체 br43×2 및 이용 방법 |
EP2319527A3 (en) | 1999-01-25 | 2011-10-12 | Biogen Idec MA Inc. | BAFF, inhibitors thereof and their use in the modulation of the B-cell response |
US20030095967A1 (en) | 1999-01-25 | 2003-05-22 | Mackay Fabienne | BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders |
US8624010B1 (en) | 1999-02-03 | 2014-01-07 | Steven K. Yoshinaga | Nucleic acids encoding B7RP1 |
US7708993B2 (en) | 1999-02-03 | 2010-05-04 | Amgen Inc. | Polypeptides involved in immune response |
US7435796B1 (en) | 1999-02-03 | 2008-10-14 | Amgen Inc. | Antibodies which bind B7RP1 |
NZ551331A (en) | 1999-02-03 | 2008-08-29 | Amgen Inc | Methods using polypeptides involved in immune response |
AU2880400A (en) | 1999-02-12 | 2000-08-29 | Amgen, Inc. | Tnf-related proteins |
KR20140094647A (ko) | 1999-03-25 | 2014-07-30 | 아비에 도이치란트 게엠베하 운트 콤파니 카게 | 사람 il-12에 결합하는 사람 항체 및 이의 제조방법 |
US20030022233A1 (en) | 1999-04-30 | 2003-01-30 | Raymond G. Goodwin | Methods of use of the taci/taci-l interaction |
AU4986700A (en) | 1999-05-06 | 2000-11-21 | National Jewish Medical And Research Center | Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof |
JP2003505020A (ja) | 1999-07-02 | 2003-02-12 | ジェネンテック・インコーポレーテッド | ペプチドリガンドドメイン及び多量体化ドメインを含む融合ペプチド |
CA2380813A1 (en) | 1999-07-29 | 2001-02-08 | Medarex, Inc. | Human monoclonal antibodies to her2/neu |
WO2001012658A2 (en) | 1999-08-11 | 2001-02-22 | Isis Innovations Limited | Human icos ligand and application thereof |
ES2282133T3 (es) | 1999-08-24 | 2007-10-16 | Medarex, Inc. | Anticuerpos frente a la ctla-4 humano y sus usos. |
JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
EP1900816A3 (en) | 1999-09-21 | 2008-03-26 | Genetics Institute, LLC | GL50 molecules and uses therefor |
PT1218504E (pt) | 1999-09-21 | 2007-10-22 | Genetics Inst Llc | Novas moléculas gl50 e suas utilizações |
CA2400214A1 (en) | 2000-02-11 | 2001-11-15 | Amgen Inc. | Fusion receptor from tnf family |
WO2001064704A1 (en) | 2000-03-02 | 2001-09-07 | Mayo Foundation For Medical Education And Research | hB7-H2, A NOVEL CO-STIMULATORY MOLECULE |
US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
CA2407910C (en) * | 2000-06-16 | 2013-03-12 | Steven M. Ruben | Antibodies that immunospecifically bind to blys |
GB0016633D0 (en) | 2000-07-07 | 2000-08-23 | Bp Exploration Operating | Process |
US6635750B1 (en) | 2000-07-20 | 2003-10-21 | Millennium Pharmaceuticals, Inc. | B7-H2 nucleic acids, members of the B7 family |
US20030091565A1 (en) | 2000-08-18 | 2003-05-15 | Beltzer James P. | Binding polypeptides and methods based thereon |
JP2004532604A (ja) | 2000-08-18 | 2004-10-28 | ダイアックス コーポレーション | Bリンパ球刺激因子タンパク質(BLyS)のための結合性ポリペプチド |
EP1337634A2 (en) | 2000-11-28 | 2003-08-27 | Amgen Inc. | Novel polypeptides involved in immune response |
WO2002057435A2 (en) * | 2001-01-18 | 2002-07-25 | Merck Patent Gmbh | Bifunctional fusion proteins with glucocerebrosidase activity |
CN1970077A (zh) | 2001-05-11 | 2007-05-30 | 安姆根有限公司 | 与tall-1结合的肽和相关分子 |
AR035119A1 (es) | 2001-08-16 | 2004-04-14 | Lilly Co Eli | Anticuerpos humanos antagonistas anti-htnfsf13b |
AU2003295411A1 (en) | 2002-11-07 | 2004-06-03 | Celltech R & D | Human monoclonal antibodies to heparanase |
ATE471946T1 (de) * | 2002-12-17 | 2010-07-15 | Merck Patent Gmbh | Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2 |
JP2006517191A (ja) | 2002-12-30 | 2006-07-20 | アムジエン・インコーポレーテツド | 共刺激因子を用いた併用療法 |
ATE455127T1 (de) | 2003-05-31 | 2010-01-15 | Micromet Ag | Humane anti-humane cd3-bindungsmoleküle |
US7271245B2 (en) | 2004-02-13 | 2007-09-18 | The Scripps Research Institute | Methods and compositions for inhibition of metastasis |
JPWO2006003999A1 (ja) | 2004-07-05 | 2008-07-31 | 財団法人化学及血清療法研究所 | ヒト抗ヒトb7rp−1抗体およびその抗体フラグメント |
CA2572765C (en) | 2004-07-08 | 2013-05-21 | Amgen Inc. | Compound having improved bioefficiency when administered in a multidose regimen |
EA011879B1 (ru) | 2004-09-24 | 2009-06-30 | Эмджин Инк. | МОЛЕКУЛЫ С МОДИФИЦИРОВАННЫМ Fc ФРАГМЕНТОМ |
SI1915398T1 (sl) | 2005-07-18 | 2016-07-29 | Amgen Inc. | Humana nevtralizacijska protitelesa proti b7rp1 |
EP1928506A4 (en) * | 2005-08-19 | 2009-10-21 | Abbott Lab | IMMUNOGLOBULIN HAVING TWO VARIABLE DOMAINS AND USES THEREOF |
PE20070684A1 (es) * | 2005-11-14 | 2007-08-06 | Amgen Inc | MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP |
RS52888B (en) | 2007-03-27 | 2014-02-28 | Zymogenetics Inc. | COMBINATION OF BLYS INHIBITION AND MYPHOPHENOLATE MOFETILE FOR THE TREATMENT OF AUTOMMUNE DISEASE |
US20090022720A1 (en) * | 2007-07-20 | 2009-01-22 | Stephan Fischer | Conjugate of an antibody against CD4 and antifusogenic peptides |
WO2009015345A1 (en) * | 2007-07-25 | 2009-01-29 | Amgen Inc. | Pharmaceutical compositions comprising fc fusion proteins |
EP2233149B1 (en) | 2007-10-16 | 2016-02-10 | ZymoGenetics, Inc. | Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for treatment of autoimmune disease |
EP2072527A1 (en) * | 2007-12-21 | 2009-06-24 | Altonabiotec AG | Fusion polypeptides comprising a SHBG dimerization component and uses thereof |
CN108864285A (zh) | 2008-01-03 | 2018-11-23 | 斯克里普斯研究院 | 通过模块识别结构域的抗体靶向 |
US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
PL2235064T3 (pl) | 2008-01-07 | 2016-06-30 | Amgen Inc | Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych |
FR2944448B1 (fr) | 2008-12-23 | 2012-01-13 | Adocia | Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes. |
WO2012162561A2 (en) | 2011-05-24 | 2012-11-29 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
AR090626A1 (es) | 2012-04-20 | 2014-11-26 | Lilly Co Eli | Anticuerpos anti-baff-anti-il-17 biespecificos |
US9458246B2 (en) * | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
JOP20140087B1 (ar) | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
US10150800B2 (en) | 2013-03-15 | 2018-12-11 | Zyngenia, Inc. | EGFR-binding modular recognition domains |
EA033604B1 (ru) | 2014-01-31 | 2019-11-08 | Boehringer Ingelheim Int | Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид |
-
2014
- 2014-03-11 JO JOP/2014/0087A patent/JOP20140087B1/ar active
- 2014-03-12 MX MX2015012440A patent/MX369502B/es active IP Right Grant
- 2014-03-12 PT PT14717310T patent/PT2968491T/pt unknown
- 2014-03-12 KR KR1020157027042A patent/KR102218723B1/ko active IP Right Grant
- 2014-03-12 AU AU2014244498A patent/AU2014244498B2/en active Active
- 2014-03-12 HU HUE14717310A patent/HUE040169T2/hu unknown
- 2014-03-12 JP JP2016501678A patent/JP6523243B2/ja active Active
- 2014-03-12 ES ES18182864T patent/ES2923909T3/es active Active
- 2014-03-12 SI SI201430908T patent/SI2968491T1/sl unknown
- 2014-03-12 PL PL14717310T patent/PL2968491T3/pl unknown
- 2014-03-12 US US14/776,399 patent/US10421823B2/en active Active
- 2014-03-12 CN CN201910521740.2A patent/CN110437336A/zh active Pending
- 2014-03-12 LT LTEP18182864.1T patent/LT3456344T/lt unknown
- 2014-03-12 CN CN201480020434.6A patent/CN105324127B/zh active Active
- 2014-03-12 AP AP2015008768A patent/AP2015008768A0/xx unknown
- 2014-03-12 KR KR1020217004604A patent/KR102361632B1/ko active IP Right Grant
- 2014-03-12 CA CA2904992A patent/CA2904992C/en active Active
- 2014-03-12 DK DK14717310.8T patent/DK2968491T3/en active
- 2014-03-12 NZ NZ711954A patent/NZ711954A/en unknown
- 2014-03-12 HU HUE18182864A patent/HUE059507T2/hu unknown
- 2014-03-12 PL PL18182864.1T patent/PL3456344T3/pl unknown
- 2014-03-12 ES ES14717310.8T patent/ES2687299T3/es active Active
- 2014-03-12 MY MYPI2015703088A patent/MY171938A/en unknown
- 2014-03-12 PE PE2015001973A patent/PE20151772A1/es unknown
- 2014-03-12 PT PT181828641T patent/PT3456344T/pt unknown
- 2014-03-12 MY MYPI2018002384A patent/MY198370A/en unknown
- 2014-03-12 EA EA201591720A patent/EA035388B1/ru unknown
- 2014-03-12 EP EP18182864.1A patent/EP3456344B1/en active Active
- 2014-03-12 RS RS20181088A patent/RS57689B1/sr unknown
- 2014-03-12 TW TW103108956A patent/TWI603978B/zh active
- 2014-03-12 LT LTEP14717310.8T patent/LT2968491T/lt unknown
- 2014-03-12 EP EP20158997.5A patent/EP3689371A1/en active Pending
- 2014-03-12 UA UAA201508877A patent/UA120034C2/uk unknown
- 2014-03-12 NZ NZ751502A patent/NZ751502A/en unknown
- 2014-03-12 UY UY0001035396A patent/UY35396A/es active IP Right Grant
- 2014-03-12 HR HRP20220884TT patent/HRP20220884T1/hr unknown
- 2014-03-12 SG SG11201507208VA patent/SG11201507208VA/en unknown
- 2014-03-12 DK DK18182864.1T patent/DK3456344T3/da active
- 2014-03-12 RS RS20220711A patent/RS63431B1/sr unknown
- 2014-03-12 SI SI201431972T patent/SI3456344T1/sl unknown
- 2014-03-12 EP EP14717310.8A patent/EP2968491B1/en active Active
- 2014-03-12 WO PCT/US2014/024908 patent/WO2014159725A1/en active Application Filing
-
2015
- 2015-09-07 IL IL241281A patent/IL241281B/en active IP Right Grant
- 2015-09-10 ZA ZA2015/06708A patent/ZA201506708B/en unknown
- 2015-09-11 MX MX2019013442A patent/MX2019013442A/es unknown
- 2015-09-11 TN TN2015000414A patent/TN2015000414A1/en unknown
- 2015-09-11 CL CL2015002600A patent/CL2015002600A1/es unknown
- 2015-09-11 PH PH12015502074A patent/PH12015502074A1/en unknown
- 2015-10-13 CR CR20150544A patent/CR20150544A/es unknown
-
2016
- 2016-06-17 HK HK16106993.6A patent/HK1218885A1/zh unknown
-
2018
- 2018-08-09 CY CY20181100835T patent/CY1120569T1/el unknown
- 2018-10-10 HR HRP20181629TT patent/HRP20181629T1/hr unknown
-
2019
- 2019-04-25 JP JP2019084291A patent/JP6825033B2/ja active Active
- 2019-09-23 US US16/579,321 patent/US11492417B2/en active Active
-
2021
- 2021-01-12 JO JOP/2021/0010A patent/JOP20210010A1/ar unknown
-
2022
- 2022-09-28 US US17/936,062 patent/US20230128444A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
HRP20220884T1 (hr) | Proteini specifični za baff i b7rp1 i njihova uporaba | |
HRP20191704T1 (hr) | Multispecifična protutijela | |
HRP20200382T1 (hr) | Humanizirana ili kimerna protutijela cd3 | |
HRP20200189T1 (hr) | Anti-tigit antitijela, anti-pvrig antitijela i njihove kombinacije | |
HRP20201031T1 (hr) | Anti-ctla-4 protutijela i postupci njihove upotrebe | |
HRP20192346T1 (hr) | Molekule anti-lag-3 antitijela i njihove uporabe | |
HRP20231579T1 (hr) | Anti-ctla-4 antitijela i postupci njihove upotrebe | |
HRP20201191T1 (hr) | Mutirani multispecifični fab fragmenti antitijela | |
HRP20211794T1 (hr) | Humana antitijela za pd-1 | |
HRP20201259T1 (hr) | Protutijela protiv ox40 i njihova upotreba | |
HRP20191608T1 (hr) | Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida | |
HRP20201993T1 (hr) | Protutijela protiv pd-1 | |
HRP20201090T1 (hr) | Protutijela anti-icos | |
HRP20210739T1 (hr) | Molekule koje vežu antigen i sadrže trimer obitelji tnf liganada | |
HRP20210364T1 (hr) | Anti-gitr antitijela i postupci za njihovu primjenu | |
HRP20210372T1 (hr) | Anti-lag3 antitijela i antigen-vezujući fragmenti | |
HRP20201747T1 (hr) | Bispecifične antigen vezujuće molekule koje aktiviraju t stanice, protiv folr1 i cd3 | |
HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
HRP20150623T1 (hr) | Monoklonalno protutijelo sposobno za vezivanje na specifiäśni diskontinuirani epitop koji se pojavljuje u podruäśju ad1 od humanog glikoproteina citomegalovirusa gb, te njegov fragment koji se veže na antigen | |
MX2014001883A (es) | Proteinas y peptidos modificados. | |
HRP20220107T1 (hr) | Proteini koji vežu kalikrein plazme | |
HRP20220787T1 (hr) | Protutijela protiv garp-tgf-beta | |
HRP20160131T1 (hr) | Protutijela koja se vežu na izvanstaniäśnu domenu 4 od ljudskog csf1r i njihova uporaba | |
HRP20230060T1 (hr) | Antitijela protiv ox40 i njihova primjena |